SIERRA NASH: Open Payments
NPI 1902455256 · CORYDON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,403 in 79 payments from 27 companies in 2025. Trend: 2023 $21 · 2024 $499 · 2025 $1,403
Food & beverage: $1,403
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $222 |
| Novo Nordisk Inc | 13 | $183 |
| AstraZeneca Pharmaceuticals LP | 5 | $169 |
| Otsuka America Pharmaceutical, Inc. | 7 | $152 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Gilead Sciences, Inc. | 2 | $50 |
| CSL Behring | 2 | $50 |
| Medtronic, Inc. | 2 | $43 |
| Exact Sciences Corporation | 2 | $40 |
Products named: REXULTI, FARXIGA, VRAYLAR, Rybelsus, Wegovy, Auvelity, VOQUEZNA, Andembry.
Industry payments across IN — which companies pay providers there.
